SCHEMBL3289845

SCHEMBL3289845

O=C(O)c1cc(CCl)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.71
CTSB P07858 1/20 0.71
MMP9 P14780 1/20 0.71
DNMT1 P26358 1/20 0.71
DNMT3B Q9UBC3 1/20 0.71
DNMT3L Q9UJW3 1/20 0.71
DNMT3A Q9Y6K1 1/20 0.71
LCK P06239 2/20 0.65
HNF4A P41235 2/20 0.62
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
KAT8 Q9H7Z6 2/20 0.56
EGFR P00533 1/20 0.56
PTGS2 P35354 2/20 0.55
CA12 O43570 1/20 0.55
ALOX5 P09917 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28761882 0.85 LCK (0.71) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL27503796 0.84 PPARA (0.56) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL29414416 0.83 KLKB1 (1.00) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL160646 0.83 KLKB1 (1.00) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL10950033 0.83 LCK (0.89) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL312283 0.82 MAOA (0.49) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL15063308 0.82 FOLH1 (0.56) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL4878532 0.82 KLKB1 (0.74) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL31550006 0.82 KLKB1 (0.74) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL30790801 0.82 LCK (0.85) KLKB1CTSBMMP9DNMT1DNMT3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105111112-A Refining process for intermediate benzsulfamide of blood glucose-reducing drug glibenclamide TIANJIN PHARMACEUTICAL GROUP GENCOM PHARMACEUTICAL 2015-12-02 CN claimed
CN-113354666-A Four kinds of D-A' - (Pi-A)2Type polymeric salicylaldehyde Schiff base derivative metal complex and preparation method and application thereof 湘潭大学 2021-09-07 CN disclosed
CN-109890821-A Amino-pyrrolopyrimidine ketone compound and its application method 艾科尔公司 2019-06-14 CN disclosed
CN-109641844-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2019-04-16 CN disclosed
CN-108884044-A PIPERIDINE DERIVATIVE 大塚制药株式会社 2018-11-23 CN disclosed
CN-105051038-B Biaryl-propanoic derivatives and its purposes as drug 赛诺菲 2018-08-03 CN disclosed
CN-104411312-B The combination for being used in treatment neurological or dysbolism use including PDE2 the inhibitor such as methyl of 1 aryl 4 [1,2,4] triazole [4,3 A] quinoxaline compounds and PDE10 inhibitor 詹森药业有限公司 2018-03-06 CN disclosed
CN-105209444-B It can be used as the benzo-fused heterocycle derivative of GPR120 activator 詹森药业有限公司 2017-12-29 CN disclosed
CN-105209444-A Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV 2015-12-30 CN disclosed
CN-105111112-A Refining process for intermediate benzsulfamide of blood glucose-reducing drug glibenclamide TIANJIN PHARMACEUTICAL GROUP GENCOM PHARMACEUTICAL 2015-12-02 CN disclosed
CN-103857657-A Heterocyclic derivative and pharmaceutical drug NIPPON SHINYAKU CO LTD 2014-06-11 CN disclosed
CN-103619846-A 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives JANSSEN PHARMACEUTICA NV 2014-03-05 CN disclosed
US-7727558-B2 Polymeric delivery agents and delivery agent compounds EMISPHERE TECHNOLOGIES, INC. (US) 2010-06-01 US disclosed
US-20070141022-A1 POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS EMISPHERE TECHNOLOGIES, INC. 2007-06-21 US disclosed
US-7208483-B2 Polymeric delivery agents and delivery agent compounds EMISPHERE TECHNOLOGIES, INC. (US) 2007-04-24 US disclosed
US-20030232085-A1 Polymeric delivery agents and delivery agent compounds EMISPHERE TECHNOLOGIES, INC. 2003-12-18 US disclosed
EP-1146860-A4 POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS EMISPHERE TECH INC (US) 2002-07-03 EP disclosed
EP-1146860-A2 POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS Emisphere Technologies, Inc. (US) 2001-10-24 EP disclosed
WO-2000040203-A2 POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS EMISPHERE TECHNOLOGIES, INC. (US) 2000-07-13 WO disclosed
US-4702999-A ANTIFOGGING AGENTS MITSUBISHI PAPER MILLS, LTD. (JP) 1987-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070141022-A1 POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS LPXN, PGF, TTPA KLKB1 1678/4885CTSB 709/4885MMP9 635/4885
US-20030232085-A1 Polymeric delivery agents and delivery agent compounds LPXN, PGF, TTPA KLKB1 1678/4885CTSB 709/4885MMP9 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.